In recent years, the use of anti-CTLA-4 antibodies has gained significant support and success in the treatment of several types of tumors; supposedly, by reinvigorating tumor-specific cytotoxic CD8+ T cells suppressed by CTLA-4-expressing Tregs (Wolchok and Saenger, 2008). Here, CD8A is linked to neoplasm.